Search
Erlotinib Action Pathway (New)
smpdb.ca/view/SMP0123148Drug actionIt reversibly binds to the intracellular tyrosine kinase ATP binding region of the epidermal growth factor receptor and acts as an inhibitor to prevent ATP from binding to the receptor at its site. … This drug is indicated to treat metastatic non-small cell lung cancer (NSCLC) with tumors showing epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.
Enzymes: Pro-epidermal growth factor, Epidermal growth factor receptorTRK-250
go.drugbank.com/drugs/DB18500InvestigationalTRK-250 is a small interfering RNA agent that targets human transforming growth factor-beta 1 (TGF-β1) messenger RNA.
Siponimod
go.drugbank.com/drugs/DB12371ApprovedInvestigational[L12171] This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA … Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS).
Categories: Immunologic Factors, Sphingosine 1-phosphate Receptor ModulatorInsulin (New)
smpdb.ca/view/SMP0127691PhysiologicalIn addition, various hormones, such as melatonin, estrogen, leptin, growth hormone, and glucagon like peptide-1 also regulate insulin secretion. … Insulin promotes glycogen synthesis, lipid synthesis, protein synthesis, DNA synthesis, and cellular growth and differentiation.
Enzymes: Growth factor receptor-bound protein 2, SHC-transforming protein 1mTOR Signaling pathway
smpdb.ca/view/SMP0535455Signalingfactor input. … factors, nutrients, cellular energy status, oxygen levels, and stress to orchestrate cell growth, metabolism, survival, and cytoskeletal organization.
Enzymes: Insulin-like growth factor I, Insulin-like growth factor 1 receptorInsulin Signalling
smpdb.ca/view/SMP0000391SignalingInsulin is responsible for the regulation of glucose levels in the body. It stimulates the storage of energy and inhibits the breakdown of high energy metabolites. Glycogen and lipid biosynthesis are upregulated, and conversely, glycogen...
Enzymes: Growth factor receptor-bound protein 2, SHC-transforming protein 1Strontium ranelate
go.drugbank.com/drugs/DB09267ApprovedWithdrawnStrontium ranelate, a strontium (II) salt of ranelic acid, is a medication for osteoporosis. … Available for prescription use for a time in some parts of the world as Protelos (strontium ranelate) 2 g granules for oral suspension by Servier, it was ultimately discontinued in 2016-2017 owing to an
Mixtures: FULLBONE D3 2 G/800 IU EFERVESAN TABLET, 30 ADET, FULLBONE D3 2 G/800 IU EFERVESAN TABLET, 60 ADETCategories: Heterocyclic Compounds, 1-RingRas Signaling Pathway
smpdb.ca/view/SMP0063784SignalingRAS signalling pathway is one of the main pathways to transduce intracellular signals in response to mitogens to controls cell growth, survival and anti-apoptotic programs. … RAS also effects exchange factors causing inhibition of transcription factors from FoxO family, part of promoting cell cycle arrest and apoptosis.
Enzymes: Transforming protein RhoA, Apoptotic protease-activating factor 1Rhein
go.drugbank.com/drugs/DB13174ExperimentalRhein is an anthraquinone metabolite of rheinanthrone and senna glycoside is present in many medicinal plants including Rheum palmatum, Cassia tora, Polygonum multiflorum, and Aloe barbadensis . It is known to have hepatoprotective, neph...
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP2C9 InhibitorsSMAD family member 2
go.drugbank.com/bio_entities/BE0004445TargetHumansReceptor-regulated SMAD (R-SMAD) that is an intracellular signal transducer and transcriptional modulator activated by TGF-beta (transforming growth factor) and activin type 1 receptor kinases. … Binds the TRE element in the promoter region of many genes that are regulated by TGF-beta and, on formation of the SMAD2/SMAD4 complex, activates transcription.
Synonyms: JV18-1